Name (Synonyms) | Correlation |
---|
Name (Synonyms) | Correlation | |
---|---|---|
D018754 | Ventricular Dysfunction NIH | 0.71 |
D018487 | Ventricular Dysfunction, Left NIH | 0.71 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
Coronavirus Disease 2019 (COVID-19) emerged in December 2019, and in mere few months has resulted in a pandemic of viral pneumonia. Substantial proportion of patients with COVID-19 have biochemical evidence of myocardial injuries during the acute phase. Possible mechanisms including acute coronary events, cytokine storm, and COVID-19 related myocarditis, have been postulated for the cardiac involvement in COVID-19. It is uncertain whether COVID-19 survivors are at risk cardiac dysfunction including cardiac arrhythmia and heart failure. The prospective screening study aims to evaluate the possible latent effects from COVID-19 in COVID-19 survivors. COVID-19 survivors 4-6 weeks after hospital discharge will be recruited from the Infectious Disease clinic, Queen Mary Hospital with standard 12-lead electrocardiogram, serum troponin, NT-proBNP, and standard transthoracic echocardiogram. The outcome measures include (1) new onset cardiac arrhythmia, (2) N Terminal (NT)-proBNP elevation above the diagnostic range of heart failure, and (3) newly detected left ventricular dysfunction.
Description: Atrial fibrillation, conduction block
Measure: New-onset cardiac arrhythmia Time: At the time of screeningDescription: Elevated NT-proBNP level above the age-specific diagnostic threshold of heart failure
Measure: Elevation of NT-proBNP Time: At the time of screeningDescription: Left ventricular systolic function
Measure: Left ventricular dysfunction Time: At the time of screening